BACKGROUND: The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The majority of mCRPC patients are elderly suffering from chronic co-morbidities requiring use of various concomitant medications. In the present study, we focused on impact of concomitant antihypertensive medication on the outcomes of mCRPC patients treated with ENZ or ABI. METHODS: In total, 300 patients were included and their clinical data were retrospectively analyzed. RESULTS: Angiotensin-converting enzyme inhibitors (ACEIs) represented the only concomitant medication significantly associated with survival. The median radiographic progression-free survival (rPFS) and overall survival (OS) for patients using ACEIs were 15.5 and 32.3 months compared to 10.7 and 24.0 months for those not using ACEIs (p = 0.0053 and p = 0.0238, respectively). Cox multivariable analysis revealed the use of ACEIs a significant predictive factor for both rPFS (HR = 0.704, p = 0.0364) and OS (HR = 0.592, p = 0.0185). CONCLUSION: The findings of this study suggest an association between the concomitant use of ACEIs and longer survival of mCRPC patients receiving ENZ or ABI therapy.

2nd Department of Internal Medicine Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Immunochemistry Diagnostics University Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Medicine and Surgery University Hospital of Parma Parma Italy

Department of Oncology and Radiotherapeutics Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Surgery University Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Urology Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic

Oncology Unit Macerata Hospital Macerata Italy

Oncology Unit University Hospital of Parma Parma Italy

See more in PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65(1):5‐29. doi:10.3322/caac.21254 PubMed DOI

Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38‐52. doi:10.1016/j.eururo.2019.08.005 PubMed DOI

Cornford P, van den Bergh RCN, Briers E, et al. EAU‐EANM‐ESTRO‐ESUR‐SIOG guidelines on prostate cancer. Part II‐2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263‐282. doi:10.1016/j.eururo.2020.09.046 PubMed DOI

Beer TM, Armstrong AJ, Rathkopf DE, et al. PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424‐433. doi:10.1056/NEJMoa1405095 PubMed DOI PMC

Ryan CJ, Smith MR, Fizazi K, et al. COU‐AA‐302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy‐naive men with metastatic castration‐resistant prostate cancer (COU‐AA‐302): final overall survival analysis of a randomised, double‐blind, placebo‐controlled phase 3 study. Lancet Oncol. 2015;16(2):152‐160. doi:10.1016/S1470-2045(14)71205-7 PubMed DOI

de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995‐2005. doi:10.1056/NEJMoa1014618 PubMed DOI PMC

Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187‐1197. doi:10.1056/NEJMoa1207506 PubMed DOI

Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis‐free survival in prostate cancer. N Engl J Med. 2018;378(15):1408‐1418. doi:10.1056/NEJMoa1715546 PubMed DOI

Fizazi K, Shore N, Tammela TL, et al. Castration‐resistant prostate cancer. N Engl J Med. 2019;380(13):1235‐1246. doi:10.1056/NEJMoa1815671 PubMed DOI

van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population‐based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448‐3456. doi:10.1200/JCO.2010.29.1567 PubMed DOI

Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012;104(17):1335‐1342. doi:10.1093/jnci/djs299 PubMed DOI PMC

Holmes S, Griffith EJ, Musto G, Minuk GY. Antihypertensive medications and survival in patients with cancer: a population‐based retrospective cohort study. Cancer Epidemiol. 2013;37(6):881‐885. doi:10.1016/j.canep.2013.09.001 PubMed DOI

Poch MA, Mehedint D, Green DJ, et al. The association between calcium channel blocker use and prostate cancer outcome. Prostate. 2013;73(8):865‐872. doi:10.1002/pros.22632 PubMed DOI PMC

Cardwell CR, Coleman HG, Murray LJ, O'Sullivan JM, Powe DG. Beta‐blocker usage and prostate cancer survival: a nested case‐control study in the UK clinical practice research datalink cohort. Cancer Epidemiol. 2014;38(3):279‐285. doi:10.1016/j.canep.2014.03.011 PubMed DOI

Cardwell CR, Mc Menamin ÚC, Hicks BM, Hughes C, Cantwell MM, Murray LJ. Drugs affecting the renin‐angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med. 2014;12:28. doi:10.1186/1741-7015-12-28 PubMed DOI PMC

Lu H, Liu X, Guo F, et al. Impact of beta‐blockers on prostate cancer mortality: a meta‐analysis of 16,825 patients. Onco Targets Ther. 2015;8:985‐990. doi:10.2147/OTT.S78836 PubMed DOI PMC

Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL. Use of β‐blockers is associated with prostate cancer‐specific survival in prostate cancer patients on androgen deprivation therapy. Prostate. 2013;73(3):250‐260. doi:10.1002/pros.22564 PubMed DOI

Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association between use of β‐blockers and prostate cancer‐specific survival: a cohort study of 3561 prostate cancer patients with high‐risk or metastatic disease. Eur Urol. 2014;65(3):635‐664. doi:10.1016/j.eururo.2013.01.007 PubMed DOI

Santala EE, Rannikko A, Murtola TJ. Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland‐a nationwide cohort study. Int J Cancer. 2019;144(3):440‐447. doi:10.1002/ijc.31802 PubMed DOI

Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Antihypertensive drug use and prostate cancer‐specific mortality in Finnish men. PloS One. 2020;15(6):e0234269. doi:10.1371/journal.pone.0234269 PubMed DOI PMC

Sivanesan S, Taskén KA, Grytli HH. Association of β‐blocker use at time of radical prostatectomy with rate of treatment for prostate cancer recurrence. JAMA Netw Open. 2022;5(1):e2145230. doi:10.1001/jamanetworkopen.2021.45230 PubMed DOI PMC

Ronquist G, Frithz G, Wang YH, Lindeborg T. Captopril may reduce biochemical (prostate‐specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Scand J Urol Nephrol. 2009;43(1):32‐36. doi:10.1080/00365590802468875 PubMed DOI

Uemura H, Hasumi H, Kawahara T, et al. Pilot study of angiotensin II receptor blocker in advanced hormone‐refractory prostate cancer. Int J Clin Oncol. 2005;10(6):405‐410. doi:10.1007/s10147-005-0520-y PubMed DOI

Wilk M, Waśko‐Grabowska A, Skoneczna I, Szmit S. Angiotensin system inhibitors may improve outcomes of patients with castration‐resistant prostate cancer during Abiraterone acetate treatment‐a cardio‐oncology study. Front Oncol. 2021;11:664741. doi:10.3389/fonc.2021.664741 PubMed DOI PMC

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205‐216. PubMed

Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin‐angiotensin systems. Physiol Rev. 2006;86(3):747‐803. doi:10.1152/physrev.00036.2005 PubMed DOI

Ager EI, Neo J, Christophi C. The renin‐angiotensin system and malignancy. Carcinogenesis. 2008;29(9):1675‐1684. doi:10.1093/carcin/bgn171 PubMed DOI

George AJ, Thomas WG, Hannan RD. The renin‐angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10(11):745‐759. doi:10.1038/nrc2945 PubMed DOI

Almutlaq M, Alamro AA, Alamri HS, Alghamdi AA, Barhoumi T. The effect of local renin angiotensin system in the common types of cancer. Front Endocrinol. 2021;12:736361. doi:10.3389/fendo.2021.736361 PubMed DOI PMC

Haendeler J, Dimmeler S. Handbook of Experimental Pharmacology. Vol 163. 1st ed. Springer; 2004. doi:10.1007/978-3-642-18495-6_4 DOI

Chappell MC. Emerging evidence for a functional angiotensin‐converting enzyme 2‐angiotensin‐(1‐7)‐MAS receptor axis: more than regulation of blood pressure? Hypertension. 2007;50(4):596‐599. doi:10.1161/HYPERTENSIONAHA.106.076216 PubMed DOI

Scott‐Emuakpor J, Allot E, Johnson SA, et al. Angiotensin receptor signaling and prostate tumor growth in mice. J Exp Ther Oncol. 2017;11(2):107‐115. PubMed PMC

Chow YW, Pietranico R, Mukerji A. Studies of oxygen binding energy to hemoglobin molecule. Biochem Biophys Res Commun. 1975;66(4):1424‐1431. doi:10.1016/0006-291x(75)90518-5 PubMed DOI

Uemura H, Ishiguro H, Nakaigawa N, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2003;2(11):1139‐1147. PubMed

Domińska K, Okła P, Kowalska K, et al. Angiotensin 1‐7 modulates molecular and cellular processes central to the pathogenesis of prostate cancer. Sci Rep. 2018;8(1):15772. doi:10.1038/s41598-018-34049-8 PubMed DOI PMC

Woo Y, Jung YJ. Angiotensin II receptor blockers induce autophagy in prostate cancer cells. Oncol Lett. 2017;13(5):3579‐3585. doi:10.3892/ol.2017.5872 PubMed DOI PMC

Singh KD, Karnik SS. Angiotensin receptors: structure, function, signaling and clinical applications. J Cell Signal. 2016;1(2):111. doi:10.4172/jcs.1000111 PubMed DOI PMC

Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin‐converting enzyme 2 and angiotensin‐(1‐7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005;289(6):H2281‐H2290. doi:10.1152/ajpheart.00618.2005 PubMed DOI PMC

Krishnan B, Smith TL, Dubey P, et al. Angiotensin‐(1‐7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate. 2013;73(1):71‐82. doi:10.1002/pros.22542 PubMed DOI PMC

Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine‐induced migration of SW 480 colon carcinoma cells is inhibited by beta‐blockers. Cancer Res. 2001;61(7):2866‐2869. PubMed

Guo K, Ma Q, Wang L, et al. Norepinephrine‐induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep. 2009;22(4):825‐830. doi:10.3892/or_00000505 PubMed DOI

Stiles JM, Amaya C, Rains S, et al. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PloS One. 2013;8(3):e60021. doi:10.1371/journal.pone.0060021 PubMed DOI PMC